C3-Cloud personalised care plan development platform for addressing the needs of multi-morbidity and managing poly-pharmacy : protocol for a pilot technology trial by von Tottleben, M. et al.
JMIR Preprints von Tottleben et al
C3-Cloud personalised care plan development
platform for addressing the needs of multi-morbidity
and managing poly-pharmacy: Protocol for a pilot
technology trial
 Malte von Tottleben, Katie Grinyer, Ali Arfa, Lamine Traore, Dolores Verdoy,
Sarah N. Lim Choi Keung, Igor Larranaga, Marie-Christine Jaulent, Esteban De
Manuel Keenoy, Mikael Lilja, Marie Beach, Christopher Marguerie, Mustafa
Yuksel, Gokce B. Laleci Ertukmen, Gunnar O. Klein, Pontus Lindman, Dipak Kalra,
Theodoros N. Arvanitis
Submitted to: JMIR Research Protocols
on: July 01, 2020
Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community
review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for
review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this
stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.
https://preprints.jmir.org/preprint/21994 [unpublished, non-peer-reviewed preprint]
JMIR Preprints von Tottleben et al
Table of Contents
Original Manuscript ..................................................................................................................................................................................................................................................................................................................................... 5
https://preprints.jmir.org/preprint/21994 [unpublished, non-peer-reviewed preprint]
JMIR Preprints von Tottleben et al
C3-Cloud personalised care plan development platform for addressing the
needs of multi-morbidity and managing poly-pharmacy: Protocol for a pilot
technology trial
Malte von Tottleben1; Katie Grinyer1; Ali Arfa1; Lamine Traore2; Dolores Verdoy3; Sarah N. Lim Choi Keung4; Igor
Larranaga3, 5; Marie-Christine Jaulent2; Esteban De Manuel Keenoy3; Mikael Lilja6; Marie Beach7; Christopher
Marguerie7; Mustafa Yuksel8; Gokce B. Laleci Ertukmen8; Gunnar O. Klein9; Pontus Lindman10; Dipak Kalra11;
Theodoros N. Arvanitis4 RT, DPhil
1empirica Gesellschaft für Kommunikations- und Technologieforschung mbH Bonn DE
2Laboratoire d’Informatique Médicale et d’Ingénierie des Connaissances pour la e-Santé, LIMICS Inserm, Sorbonne Université, Univ Paris 13
Paris FR
3Kronikgune, Institute for Health Services Research Barakaldo ES
4Institute of Digital Healthcare (IDH), WMG University of Warwick Coventry GB
5Basque Health Service (Osakidetza), Debagoiena Integrated Healthcare Organisation, Research Unit Arrasate-Mondragón, Guipúzcoa ES
6Unit of Research, Education, and Development Östersund, Department of Public Health and Clinical Medicine Umeå University Umeå SE
7South Warwickshire NHS Foundation Trust Warwick GB
8SRDC A.S. Ankara TR
9School of Business, Informatics, Örebro University Örebro SE
10Medixine Espoo FI
11University of Gent Gent BE
Corresponding Author:
Theodoros N. Arvanitis RT, DPhil
Institute of Digital Healthcare (IDH), WMG
University of Warwick
IDH, International Digital Laboratory
Lord Bhattacharyya Way
Coventry
GB
Phone: +44(0)7796 707955
Email: t.arvanitis@warwick.ac.uk
Abstract
Background: There is an increasing need to organise the care around the patient and not the disease, as well as taking into
account the complex realities of multiple physical, psycho-social conditions and polypharmacy. Integrated patient-centred care
delivery platforms have been developed for both patients and clinicians. These platforms could provide a promising way to
achieve a collaborative environment that improves the provision of integrated care for patients via enhanced ICT solutions.
Objective: The C3-Cloud project has developed two collaborative computer platforms for patients and members of the Multi-
Disciplinary Team and deployed these in three different European settings. The objective of this study is to pilot test the
platforms and evaluate their impact on patients, informal caregivers, healthcare professionals and, in extend, healthcare systems.
Methods: This paper describes the protocol for conducting an evaluation of the user-centred design, user experience,
acceptability, and usefulness of the platforms. For this, four ‘testing and evaluation’ phases have been defined, involving
multiple qualitative methods, and advanced impact modelling.
Results: The technology trial in this 4-year funded project (2016-2020) is currently in its execution phase. The testing and
evaluation phase 1 and 2 have been completed with satisfying results on system component tests, and promising results on
application and usability tests. The pilot technology trial for evaluation phase 3 and 4 was launched in August 2019. Data
collection for these phases is underway and results are forthcoming, approximately in April 2020. We believe that the phased,
iterative approach taken is useful as it involves relevant stakeholders at crucial stages in the platform development and allows for
https://preprints.jmir.org/preprint/21994 [unpublished, non-peer-reviewed preprint]
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a sound user acceptance assessment of the final product.
Conclusions: Patients with multiple chronic conditions often experience shortcomings in the care they receive. It is hoped that
personalised care plan platforms for patients and collaboration platforms for members of Multi-Disciplinary Teams can help to
tackle the specific challenges of clinical guideline reconciliation for multimorbid patients and improved the management of poly-
pharmacy. The initial evaluative phases have indicated promising results of platform usability. The phased methodology has
shown useful results in the first two phases, while results of phase 3 and 4 are pending. Clinical Trial:
https://www.clinicaltrials.gov/ct2/show/NCT03834207
(JMIR Preprints 01/07/2020:21994)
DOI: https://doi.org/10.2196/preprints.21994
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Abstract
Background There  is  an  increasing  need  to  organise  the  care  around  the
patient and not the disease, as well as taking into account the complex realities
of  multiple  physical,  psycho-social  conditions  and  polypharmacy.  Integrated
patient-centred care delivery platforms have been developed for both patients
and clinicians.  These platforms could  provide  a  promising  way to  achieve a
collaborative  environment  that  improves the  provision  of  integrated care for
patients via enhanced ICT solutions.
Objectives  The C3-Cloud project  has  developed two collaborative  computer
platforms for patients and members of the Multi-Disciplinary Team and deployed
these in three different European settings. The objective of this study is to pilot
test the platforms and evaluate their impact on patients, informal caregivers,
healthcare professionals and, in extend, healthcare systems.
Methods This paper describes the protocol for conducting an evaluation of the
user-centred  design,  user  experience,  acceptability,  and  usefulness  of  the
platforms.  For  this,  four  ‘testing  and evaluation’  phases  have  been defined,
involving multiple qualitative methods, and advanced impact modelling.
Results The  technology  trial  in  this  4-year  funded  project  (2016-2020)  is
currently in its execution phase. The testing and evaluation phase 1 and 2 have
been  completed  with  satisfying  results  on  system  component  tests,  and
promising results on application and usability tests. The pilot technology trial for
evaluation phase 3 and 4 was launched in  August 2019.  Data collection for
these phases is underway and results are forthcoming, approximately in April
2020.  We  believe  that  the  phased,  iterative  approach  taken  is  useful  as  it
involves relevant stakeholders at crucial  stages in the platform development
and allows for a sound user acceptance assessment of the final product. 
Conclusion Patients  with  multiple  chronic  conditions  often  experience
shortcomings in the care they receive. It is hoped that personalised care plan
platforms  for  patients  and  collaboration  platforms  for  members  of  Multi-
Disciplinary Teams can help to tackle the specific challenges of clinical guideline
reconciliation for multimorbid patients and improved the management of poly-
pharmacy.  The  initial  evaluative  phases  have  indicated  promising  results  of
platform usability. The phased methodology has shown useful results in the first
two phases, while results of phase 3 and 4 are pending.
Trial registration https://www.clinicaltrials.gov/ct2/show/NCT03834207
Keywords:  multimorbidity,  polypharmacy,  guidelines  reconciliation,  clinical
decision support, personalised care plans, diabetes mellitus type 2, heart failure,
depression, renal failure, acceptability, usability, evaluation, user-centred design
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Introduction 
Older  age  is  associated  with  an  increased  accumulation  of  multiple  chronic
conditions  called  multi-morbidity  and  includes  functional  and  cognitive
impairments.  More  than half  of  all  older  people  have  at  least  three chronic
conditions  and a significant  proportion have five or  more  [  CITATION  Lup08  \l
1031  ]. Chronic  diseases  take many forms  such as  hypertension,  depression,
diabetes renal failure. They are the main reason for poor health and a restricted
activity. They affect over one third of the European population and represent
70% of the healthcare expenditure in Europe [ CITATION Ret12 \l 1031  ]. 
The management of care for patients with multi-morbidity is more complex and
time consuming than those with  a  single  disease  [  CITATION  Aus07  \l  1031   ].
Managing multiple diseases concurrently creates an added challenge for health
service  delivery  and provision.  Therefore,  many individuals  with  chronic  and
long-term care needs experience shortcomings in the care they receive. One
reason  for  this  is  the  inconsistency  across  single-disease  clinical  guidelines
when  they  cover  situations  with  more  than  one  disease.  Current  European
medical models are often dictated by national clinical guidelines, which focus
primarily  on  managing  a  single  disease.  Evidently,  this  can  cause
inconsistencies and contradictory information when providers are following more
than  one  guideline  for  their  patient.  Furthermore,  it  can  result  in  avoidable
inefficiency  for  patients  and  health  systems,  for  example  incompatible
treatment  regimens and duplicate  clinical  visits  and tests  [  CITATION  Gut12  \l
1031  ].
Polypharmacy,  induced  by  multi-morbidity,  is  itself  an  important  factor  that
leads to an increased risk of further complications in the provision of safe and
effective care for patients, as well as the increased potential for adverse drug
interactions and events  [  CITATION NHS13 \l  1031 ].   Because of polypharmacy
redundancy and duplication of  medication is  common: it  not  rare for elderly
patients to be taking nine or more medications concurrently [ CITATION Haq09 \l
1031 ]. This current approach of managing multi-morbidity also fails to integrate
care  across  providers  and  the  interactions  of  chronic  diseases  and  their
treatments is overlooked [ CITATION Pav12 \l 1031 ]. As the number and complexity
of health conditions increase with age, the type and number of care providers
also increase. This often leads to fragmented care: it becomes significantly more
difficult for providers to align and coordinate care teams and settings. This is
exacerbated by poor inter-professional communication and lack of appropriate
information sharing infrastructure that exist in many health systems and even at
local level. Without secure information exchange among the actors involved in
health,  social  and  informal  care  services,  it  becomes  almost  impossible  to
reconcile  potentially  conflicting  treatment  plans  or  avoid  potentially  harmful
interventions. An insufficient information exchange complicates the application
of data processing techniques developed under paradigms such as data science,
machine learning and artificial intelligence that could support medical decision
making with information analysis and predictive models.
Moreover, patients and their informal caregivers often do not have a voice in the
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management of their own care. This can lead to patients feeling disempowered,
less  well  informed  and  therefore  less  likely  to  follow  the  treatment  regime
“imposed” on them. Among elderly people, non-compliance has a prevalence of
25-75% and the likelihood rises in proportion to the number of drugs and daily
doses prescribed [ CITATION Gel11 \l 1031  ]. There is an increasing need to focus
care organisation around a patient with multiple diseases, rather than targeting
each disease separately. This requires a patient-centred approach: considering
each patient’s  multiple  physical  conditions,  psycho-social  conditions  and the
realities  of  multi-morbidity  and  polypharmacy.  An  interactive  collaborative
environment is needed to address these issues in the current care of patients
with multi-morbidities. 
Figure 1:  C3-Cloud platform aims
In  response,  C3-Cloud  a  European  Commission  supported  Horizon  2020
innovation project was created to pilot test collaborative computer platforms for
patients  and  for  members  of  the  Multi  Disciplinary  Team  (MDTs)  in  three
different European settings. The platform’s aims are to improve the provision of
integrated care for patients with multi-morbidity, resolve guideline conflicts (by
reconciliation  of  varying,  and  potentially  conflicting,  recommendations  from
single  disease  clinical  guidelines),  support  clinical  decision  making  through
clinical  decision  support  services  and  facilitate  communication  among  MDT
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members and with the patients through an interoperable platform (see  Figure
1).  Traditional,  “paper  based”  health  records  have  strong  limitations  for  the
integration  of  care  or  collaborative  decision  making  and  electronic  health
records (EHRs) attempt to widen the scope of health records[ CITATION Eva16 \l
1031 ]. As the healthcare landscape is ever changing, EHRs have the potential to
replace paper records and add many more capabilities, beyond mere replication
of data in an electronic format. New tools such as C3-Cloud can enhance the
interaction among MDTs, patients and their informal caregivers. The objective of
the study is to determine the impact the platform will have on patients, MDT
members and health systems with the guiding research question being: “Is the
use  of  a  personalised  ICT  tool  that  facilitates  coordinated  care  planning,
treatment  optimisation  and  patient  self-management  acceptable  to  patients
with multiple long-term conditions and their team of health professionals?”. The
overall C3-Cloud system architecture is shown in Figure 2 and Table 1 describes
the main components of the C3-Cloud system. 
The purpose of this paper is to present the research protocol of the C3-Cloud
technology trial, as a sustainable protocol guiding the development, testing and
evaluation of other interactive healthcare platforms targeting patients and MDT
members.
https://preprints.jmir.org/preprint/21994 [unpublished, non-peer-reviewed preprint]
JMIR Preprints von Tottleben et al
Figure 2: Overall C3-Cloud Architecture
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The C3-Cloud system aims to facilitate the realization of two main components: the
Coordinated Care & Cure Delivery Platform (C3DP) and the Patient Empowerment
Platform (PEP). It also involves a variety of other components: The clinical decision
support modules (CDSM), the interoperability middleware which includes modules of
technical  and semantic interoperability,  as well  as privacy and security.   All  these
components constitute the solution that will be used for the technological trial of the
C3-Cloud application.
The  Coordinated  Care  and Cure  Delivery  Platform (C3DP) is  an innovative
online means for  Multi-Disciplinary Team (MDT) members to collaboratively
manage (execute, monitor, update) the integrated personalized care plans for
patients  with  multi-morbid  conditions.  The  health  professional  will  have  a
personal log-in account. MDT members and patients have the ability to send
messages via the messaging portal to each other. The aim of the C3DP is the
creation and execution of personalised care plans for multi-morbid patients,
with the help of Clinical Decision Support Modules (CDSM) for recommendation
reconciliation, poly-pharmacy management and goal setting. 
The Patient Empowerment Platform (PEP) is  for patients and their  informal
caregivers to access their care plans online and support them in self-managing
their  care. It  aims to improve the interaction between patients  and health
professionals  and  to  collect  relevant  information  (home-based  self-
measurement data on blood pressure and weight) to enable the monitoring of
care plan related activity status and progress. Clinicians can send medication
or lifestyle change reminders as well as answer questions patients might have
about their care.
The Technical Interoperability Suite (TIS) enables health data sharing between
C3-Cloud high-level components, including information systems of local care
providers and tele-monitoring devices, in order to support integrated care plan
development, care plan progress monitoring and evaluation, as well as patient
engagement across multiple care settings.
The Semantic Interoperability Suite (SIS) handles structural mappings among
different information models and resolves semantic mismatches due to use of
different  terminology  systems  and  different  compositional  aggregations  to
represent the same clinical concept.
The  Security  and  Privacy  Suite  (SPS) guarantees  authentication  and
authorisation of members of the MDT while they are managing personalised
care plans of patients and accessing sensitive personal data. The SPS ensures
that  data  exchange  within  and  across  C3-Cloud  software  components  is
encrypted and audited properly.
Clinical  Decision  Support  Module  (CDSM) provides  guideline-based  alerts,
reminders or suggestions to support clinical pathways, and implements widely
accepted polypharmacy criteria  and risk  assessment algorithms to  support
care plan reconciliation and patient risk stratification.
https://preprints.jmir.org/preprint/21994 [unpublished, non-peer-reviewed preprint]
JMIR Preprints von Tottleben et al
Table 1: C3-Cloud terminology (accompanying Figure 1)
Methods 
Overview 
The C3-cloud study uses a mixed method research design to gain insights into
the usability, acceptability and usefulness of the C3-Cloud system. The project
has developed the innovative care planning system called ‘C3-Cloud’ which is
being  tested  with  patients,  their  informal  caregivers  and  healthcare
professionals  in  the  United  Kingdom  (South  Warwickshire),  Sweden  (Region
Jämtland  Härjedalen)  and  Spain  (Basque  Country).  The  tests  and  evaluation
activities generate data to assess the usability and usefulness of the C3-Cloud
system as well as its acceptance and satisfaction among user groups. The study
is  designed  to  go  through  four  evaluation  phases.  The  adoption  of  phases
corresponds to the study’s aims to develop the C3-Cloud system together with
its  users  in  an  iterative  approach  of  testing,  feedback  and  subsequent
improvements which corresponds to the UK’s Medical Research Council (MRC)
recommendations  for  carrying out  complex  interventions.  The MRC suggests
employing  modelling  and  exploratory  trials  before  aiming  to  carry  out
randomised controlled trials  [ CITATION Cra08 \l 1031 ]. Following this advice, the
project has been designed to evaluate through four phases (Figure 3).
Study development and timeline  
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Phase 1 and phase 2 of the
evaluation  have  been
completed  iteratively
during  C3-Cloud
development  with  a
restricted  number  of
selected  participants.
They  were  carried  out
before  the  technology
trial  over  the course of
two  and  a  half  years
(2016-2018).
Subsequently,  the  C3-
Cloud system has  been
deployed  at  the  pilot
sites,  which  is  followed by
the pilot phase 3 with a
larger number of  users.
The project aims for a 7-
months  exploratory
technology  trial  (phase 3)
and  the  final  phase  4 will
be  the  remaining  time for
system  acceptance
analysis  and  impact
assessment of C3-Cloud
(Figure  3).  All  test
participants’  data,
patient  and  clinician  data  are  retrieved  anonymously  or  anonymized  and
aggregated in the pilot sites before sharing the datasets for analysis. Control
group data for the period of phase 4 will be extracted from care centres in the
pilot  sites  in  February  2020.  Information  retrieved  will  be  on  health  care
resource consumption and it will be anonymized. To ensure that data cannot be
traced,  the  data  extracts  will  not  include  demographic  descriptors  and
identifiers.  Data  entry  of  resource  utilization  dates  will  be  manipulated
automatically and randomly within a range of +/- 30 days for each entry.
Phase 1
User-centred design
C3-Cloud system mock-ups (screenshots of the early platforms) were shown to
experts and potential platform users in the three pilot sites to evaluate the user-
centred design from the very beginning of the project. A mock-up is a prototype
if  it  provides at  least  part  of  the  functionality  of  a  system and enables  the
testing of a design. The most common use of mock-up in software development
is to create user interfaces that show the end user what the software will look
Figure 3: C3-Cloud system evaluation phases
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like without having to build the software or the underlying functionality. Mock-
ups are intuitive to users, give a realistic perspective and allow for early testing
and revision of the development plans.
In order to increase the feedback received from the end users, the evaluation of
the PEP was performed in the three pilot sites on different dates, using the most
recent available versions of the platform as mock-ups. The target size for the
test participant groups was defined as ~4 patients and 13 MDT members at
each pilot site based on convenience sampling and availability (Error: Reference
source not found). In all settings, high-level system information was provided to
testers with the aim to give them a general understanding of the project and the
C3-Cloud system. The main platforms (C3DP and PEP) with the main foreseen
functionalities were explained in detail. Finally, a discussion took place on the
basis  of  the  testers’  comments  and  inputs.  Screenshots  were  reviewed  and
comments on the presented information was then sent in writing to the software
developers. 
The discussions were moderated by a set of 7 questions [ CITATION Bar19 \l 1031 ]: 
1. To  what  degree  do  you  think  the  use  of  the C3-Cloud  services
can contribute to improving your understanding of health information that
you receive from health professionals, as well as information received in a
written form such as test results, medical reports, etc.? 
2. To what degree do you think the use of the C3-Cloud services will help you
better  understand  your  health/disease,  its  possible  developments,  and
treatment options available? 
3. Do you think the use of the C3-Cloud services will contribute to making
you become more involved in monitoring your health status and treatment
progress, and if so to what degree?
4. To what extent do you think the use of the C3-Cloud services will  help
you better adhere to treatment plans and lifestyle adjustments? 
5. Do you think the use of the C3-Cloud services will help you become more
actively involved during a consultation with healthcare professionals, and
if so to what extent?
6. How will the use of the C3-Cloud service impact on your relationship with
healthcare professionals?
7. Other issues emerged in respect of empowerment
In addition,  the system design was discussed along the topics “functionality;
content; language used; the level of data detail and user-friendliness”.
Component testing
The C3-Cloud system components include the C3DP, PEP, the clinical decision
support module (CDSM), the technical interoperability suite (TIS), the semantic
interoperability suite (SIS) and the security and privacy suite (SPS).  For all six
software components,  templates based on the IEEE 829 standard  [  CITATION
IEE08 \l 1031 ] were used, which defines a set of documents to use in software and
system test documentation. Rather than developing the full set of distinct IEEE
829 standard’s template for all components, a pragmatic approach was followed
after considering the workload implications among the technical  team. Thus,
technical  partners  agreed  on  component  test  plans  and  test  design  topics
focusing on relevant features to test in the scope of C3-Cloud. The test plan
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objectives were to i)  define the scope of what will  be tested;  ii)  specify  the
approach  taken  to  testing  and  iii)  specify  how  the  testing  results  will  be
evaluated. Then each component owner conducted the testing independently. In
addition, a form [CITATION Tra18 \l 1031 ] for the test results, which gathers the
test execution description, test data and results, as well as incident reports and
a conclusion, were developed for each component by its owner. The pragmatic
approach permitted to  obtain  component  testing  results  by  focusing  on key
features to be tested within the C3-Cloud project. Test cases for the components
were defined along specified technical software requirements for the C3-Cloud
system.
Phase 2
Application testing
For phase 2, the target size for the test participants was defined as a total of 52
MDT members and 40 patients: 16 MDTs and 20 patients in the Basque Country;
20 MDTs and 10 patients in Region Jämtland and 16 MDTs and 10 patients in
South Warwickshire, based on convenience sampling and availability in the pilot
sites (Error: Reference source not found). It was planned to apply convenience
sampling  among  people  with  sufficient  English  language  proficiency  and
proximity  to  the  local  project  managers  or  clinicians  as  to  allow  for  swift
recruitment of  participants.  All  participants received login credentials  for  the
online demonstrators of the C3DP and the PEP and training material including a
walkthrough that guides them through certain activities on the demonstrators. A
language  facilitator  from  the  pilot  sites  moderated  each  session  and  was
available for any question that was raised from the participants. The application
testing included a questionnaire on the integration of the system components
(Delphi method)  [ CITATION Dal631 \l 1031 ], a questionnaire on user interaction
satisfaction (QUIS7), the collection of ‘unstructured, oral feedback’ during the
test  session  and  ‘product  reaction  cards’  (PRCs)  [  CITATION  Bar10  \l  1031  ]
[ CITATION Ben02 \l 1031 ]. The methods are explained below.
Table 2: Number of trial participants in phase 1 and 2
Phase 1 –
User
Centred
Design
Phase 2 – Usability /
Usefulness
Pilot Region
Pa
tie
nt
s
M
D
T
m
em
be
rs
H
ea
lth
 IC
T
E
xp
er
ts
Pa
tie
nt
s
M
D
T
m
em
be
rs
South
Warwickshi
re
5 8 4 10 16
Basque
Country
5 8 - 20 16
Jämtl nd
Härjedalen
5 14 - 10 20
Total 15 30 40 52
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The  Delphi  method [  CITATION  Dal631  \l  1031   ] was  used  for  the  creation  of
questionnaire items to evaluate how people interact with the software and tests
the  integration  of  all  C3-Cloud  components.  Pilot  application  scenario
requirements  (PARs)  were  specified and matched with  C3-Cloud  specific  use
cases for four user profiles: patients, informal caregivers, members of the MDT
and healthcare professionals. Questionnaire items were developed for each use
case and tested with a clinician and an ICT developer in line with the Delphi
method step “brainstorming”.  In  the  steps  “refining and prioritization”  these
questionnaires  were  merged  into  two  questionnaires:  one  for  MDTs  and
healthcare  professionals  and  one  for  patients  and  their  informal  caregivers,
while dropping irrelevant items,   following the maxim “as little as possible, as
much as required”. Finally, the questionnaires were built on an online platform
for test participants to complete them at the end of the test session.
Usability testing
An  early  usability  testing was  performed  with  the  Questionnaire  on  User
Interaction  Satisfaction  (QUIS7)[  CITATION  Nor19  \l  1031  ].  It  measures users’
attitudes towards the  following interface  factors:  screen factors,  terminology
and system feedback, learning factors, system capabilities, technical manuals,
on-line tutorials,  multimedia,  voice recognition,  virtual environments,  internet
access and software installation. After the participants finalized the test session,
they answered the QUIS7 online. 
Product reaction cards
The product reaction cards method [ CITATION Bar10 \l 1031 ].was used as a fast
and simple method used for an overall evaluation of the users’ perception of the
software  design.  The  principle  of  this  method  is  that  it  does  not  rely  on  a
questionnaire or rating scales. The participants were presented a predefined list
of 118 words (see Figure 4 [ CITATION Ben02 \l 1031 ]) and asked to pick five words
that best describe the product or how using the product made them feel. The
descriptive  analysis  was  used  to  report  testers’  perception  of  the  C3-Cloud
system design.
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Figure 4: complete set of 118 Product Reaction Cards
Unstructured feedback
Any unstructured user feedback given during the test sessions was recorded in
writing by the session moderators both for the C3DP and the PEP. Feedback from
the different pilot sites complemented each other. There is general feedback on
the platform and specific feedback on system functionalities or flaws that were
experienced  during  the  testing.  Where  it  was  needed,  the  feedback  was
supported with screenshots. The unstructured feedback was used for a report to
the software development team.
Heuristic evaluation
A  heuristic  evaluation[  CITATION  Nie951  \l  1031  ] of  the  C3-Cloud  system was
performed to systematically identify any usability problems in the user interface
design. Issues are classified in a number of recognized usability principles – the
‘heuristic categories’. 
Five  usability  evaluation  reviewers  from  the  Institute  of  Digital  Healthcare,
University of Warwick, UK, conducted the Heuristic Evaluation in June 2018. The
spread  of  expertise  of  the  reviewers  ranged  from  systems  and  software
engineers, to clinical scientist, with experience in using, as well as developing
health IT systems. The heuristic evaluation was performed via following steps: 
1) Reviewers  attended  a  thirty  minutes  presentation  that  explained  the
purpose of  the evaluation,  the  process  that  would  be  followed and its
documentation, as well as the definition of the heuristics that would be
reviewed. 
2) Reviewers  reviewed  C3-Cloud  system  manuals,  which  describe  the
functionality  and  an  example  walkthrough,  designed  by  the  system
developers, to ensure coverage of the entirety of functionality and menus
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that can be accessed through the interfaces. 
3) The  reviewers  made  a  first  structure-free  evaluation  of  the  interfaces,
keeping unstructured text notes.  
4) A second structured pass was done by following the workflows described
in the manuals; comments were classified under each heuristic. 
5) Based on the comments collected, reviewers filled out a spreadsheet with
common  issues  for  each  heuristic  category,  further  structuring  the
process, ensuring that all interfaces had been considered for all issues of
interest.  The  spreadsheet  also  requested  a  subjective  evaluation  of
frequency  of  each  issue,  along  with  a  reviewer-based  assessment  of
criticality for each issue. Frequency and severity were combined to create
an overall risk metric that will prioritize the modifications by the technical
teams. 
The technology trial in phase 3 and phase 4
Study setting 
A technology trial will be used to test the C3-Cloud system with MDT members,
patients  and their  informal  caregivers  (when available).  The technology  trial
runs  approximately  7  months  and  take  place  in  three  European  pilot  site
regions:  Basque  Country,  Spain;  Jämtland  Härjedalen,  Sweden;  and  South
Warwickshire, UK. Study settings will include various locations that are relevant
for the provision of  health care,  e.g.  healthcare centres,  general  practitioner
(GP) offices, hospitals and patients’ homes. The technology trial registration is
under https://www.clinicaltrials.gov/ct2/show/NCT03834207.
Sampling and recruitment 
The recruitment period for patients starts 3 months before the launch of the
pilot test to allow sufficient time for the identification of eligible participants and
obtaining  informed  consents,  while  also  keeping  the  time-period  between
recruitment and piloting start as short as possible.
MDT  members  will  be  contacted  individually  by  pilot  site  managers  using
convenience sampling, taking into account their individual profiles, willingness
to participate and a few general inclusion criteria (Table 4). This non-probabilistic
sampling involves the sampling of MDT members that are nearby, aiming for a
total sample size of 62 across the three pilot sites. 
For the iterative evaluation phase 3 and phase 4 we defined the patient number
that we need to observe based on power calculations as the “observation goal”,
which is 420 patients. An unknown number of patients may withdraw from their
participation during the technology trial. Thus we added a 25% dropout margin
to the observation goal,  summing up to 526 patients to be recruited for the
piloting  trial  participation  (the  “recruitment  goal”).  It  is  anticipated  that  a
number of patients that will be approached for participation, will decline from
the outset.  Accordingly,  the  number  of  patients  that  will  be  approached for
participation (the “approaching goal”) will be 16% larger than the recruitment
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goal, summing up to 610 intervention patients across the three pilot sites. The
number  of  comparator  patients  whose  resource  consumption  data  will  be
monitored anonymously will  match the intervention patient numbers at each
pilot site. 
Potential  candidates  will  be  selected  through  each  pilot  site  screening their
databases for  eligible  patients who meet the inclusion and exclusion criteria
(Table  4). No  inclusion  criteria  for  informal  caregivers  have  been  defined,
however, exclusion criteria will  be applied (Table 4).  Once the pilot sites have
provided a list of eligible patients, they will be randomised as study candidates
to  avoid  selection  bias.  A  first  randomization  round  generates  lists  with  a
number  of  candidates  that  is  16% larger  than the  actual  recruitment  target
(including  a  25%  dropout  rate)  of  patients  per  pilot  site  and  to  adjust  for
patients that are approached but deny their participation.
Table 3 details the number of involved participants per pilot site and evaluation
phase. The number of trial participants in each pilot site for evaluation layer 4
reads as follows: “minimum number of trial participants as calculated for the
observation goal + 25% dropout rate (“recruitment goal”)  + 16% denial rate
(“approaching goal”)” and sums the total number of trial participants that will
be approached for participation.
Phase 3 -
Exploratory trial
for application
evaluation
Phase 4 – Monitoring to
model large scale impact
Pilot Region Patients MDT
members
Patients Compar
ator
patients
MDT
membe
rs
South
Warwickshire
50 16 70+18+1
4
102 16
Basque
Country
50 16 175+44+
35
254 16
Jämtland
Härjedalen
50 30 175+44+
35
254 30
Total 150 62 610 610 62
Table 3 Number of trial participants to approach
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Figure 5: Trial participant cohorts
Research assistants at each site will contact (email, mail, phone or face-to-face
meetings) the selected study candidates and provide them with material and
information about  the study and its  objectives.  Supportive activities  such as
videos and presentations may be used in a supplementary role to clarify any
questions.  Candidates  who  agree  to  participate  in  the  study  must  sign  an
informed  consent  form  for  documentation  to  confirm  they  have  read  and
understood the information and want to participate in the technology trial.
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Inclusion criteria Exclusion criteria Inclusion criteria for
MDT members
Exclusion criteria for
informal caregivers
Patients must be aged 55 or
older 
Patients are aged 54 or below
The  MDT  member
would  normally  be
involved  in  the
selected patients care.
They  are  aged  17  or
below
They  are  multimorbid  patients
that suffer from two or more of
the following four conditions in
various disease combinations:
 Type II Diabetes
 Renal  Failure  with
estimated  or  measured
glomerular  filtration  rate
(GFR/eGFR) of 30 – 59
 Heart  Failure  in
compliance with NYHA I-II
(New  York  Heart
Association  classification
of heart failure)
 Mild  or  moderate
Depression
They  suffer  from  any  of  the
following conditions:
 Severe Renal Failure with
GFR/eGFR <30
 Severe  Heart  Failure  in
compliance with NYHA III-
IV 
 Severe Depression
The  MDT  member
should be open to new
ways  of  working,
specifically as part of a
MDT  (including  GPs;
consultant  nurses  or
specialist  nurses;
district  nurses;  social
workers;  consultants;
physiotherapists  or
pharmacists).
They are not  available
most  of  the  time  in
person  or  via
telephone,  email,  SMS
or  other  means  to
respond  to  calls  for
help.
They  still  live  and  generally
plan on living in their home (or
in the community) for the trial
duration.
They live in a care institution,
for  instance  in  a  residential
home or nursing home.
The  MDT  member
should be open to the
use of new technology:
MDT  members  do  not
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Inclusion criteria Exclusion criteria Inclusion criteria for
MDT members
Exclusion criteria for
informal caregivers
have  to  be
technologically
knowledgeable  but
they  should  be  willing
to  learn  how  to  use
technology  to  support
their work.
They or their informal caregiver
pass an ICT Handling Self-Check
They  or  their  informal
caregivers do not pass the ICT
Handling  Self-Check  (i.e.  they
do not have access to suitable
IT  devices  and  do  not  have
some  familiarity  with  the  use
of ICT).
They do not have some
familiarity with the use
of  ICT  or  do not  have
the  capability  to  help
the patient out with ICT
usage if necessary.
They  are  able  to  provide
informed consent.
They  are  unable  to  provide
informed  consent  for  trial
participation.
They  are  able  to
provide  informed
consent.
They  are  unable  to
provide  informed
consent  for  trial
participation.
They,  or  their  informal
caregiver, have stable access to
the internet and at least one of
the  following  devices  readily
available  to  use  the  C3-Cloud
components:  Computer;
Notebook;  Smartphone;  Tablet.
This includes the use of Internet
They have disabilities or other
health  conditions  that  would
prevent  their  active
involvement  in  the  study
project or which prevent them
from  carrying  out  essential
functions of the trial.
They  do  not  have
stable  access  to  the
internet  and  at  least
one  of  the  following
devices  readily
available  to  use  the
C3-Cloud  components:
Computer;  Notebook;
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Inclusion criteria Exclusion criteria Inclusion criteria for
MDT members
Exclusion criteria for
informal caregivers
Browsers to open the C3-Cloud
patient dashboards online.
Smartphone;  Tablet.
This includes the use of
Internet  Browsers  to
open  the  C3-Cloud
patient  dashboards
online.
They  have  other  debilitating
conditions  that  impair  their
decision  making  capability  or
their life expectancy (e.g. end-
of-life  patients  or  cancer
patients). Patients with further
chronic diseases and other co-
morbidities  or  symptoms,  for
example,  frailty,  sleeping
problems,  malnourishment  or
anxiety,  will  not  be  excluded
from  recruitment.  Informal
caregivers  who  pass  the  ICT
Handling  Self-Check  can
substitute for the patient if the
patient does not pass the ICT
Handling  Self-Check  –  the
patient-informal  caregiver  pair
can still be recruited
They  have  debilitating
conditions  that  impair
their  decision-making
capability.
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Inclusion criteria Exclusion criteria Inclusion criteria for
MDT members
Exclusion criteria for
informal caregivers
They do not speak the regional
language:  English  for  SWFT;
Spanish  for  the  Basque
country; Swedish for RJH
They do not speak the
local language: English
for  SWFT;  Spanish  for
the  Basque  country;
Swedish for RJH
Their health care expenses are
covered  by  a  private
insurance: in the C3-Cloud pilot
sites,  private  insurances  have
no data exchange with EHRs.
Table 4: Inclusion and exclusion criteria for patients and informal caregivers
Study procedure
Early in the pilot technology trial, there is training for all participants in how to use the platforms. The pilot technology
trial is used to evaluate the user experience, satisfaction and acceptability of the C3-Cloud application as well as the
patient training material (phase 3). It also serves to obtain anonymous patient data on resource usage for the impact
modelling and sustainability planning for up scaling C3-Cloud in phase 4. At the start of the trial the patients have a
care plan created on the C3-Cloud system that they develop and manage with their healthcare professionals during
the study. Once the patient’s care plan is prepared, they are given access to the C3-Cloud system and can view and
update  their  care  plan  whenever  they  wish.  Moreover,  patients  are  able  to  send  messages  to  their  care  team
members via the system. The patients care plan in the C3-Cloud system is reviewed and adapted each time they visit
a healthcare professional that is also taking part in the study.
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In the final phase of the project a comparison will be made on the care and treatment received by patients that have
used the system and those that have not (comparator patient group). The comparator group data will be taken from
similar  patients  and  retrieved  anonymously  from  the  local  healthcare  systems.  This  data  will  contribute  to
determining the full impact of C3-Cloud by assessing the use of resources and medication across both groups of
patients (phase 4).
Phase 3 
This phase will evaluate the user experience, satisfaction and acceptability of the C3-Cloud application and patient
training material by collecting evaluation data. Data will be collected from a subset of participants - 150 patients and
52 MDT members from questionnaires they have completed. In phase 3 data on user experience and satisfaction will
be collected from training material questionnaire and QUIS questionnaire. The data collected on acceptability of the
technology will be taken from a refined version of the UTAUT questionnaire. The questionnaires will be administered
as one online survey a few weeks after the trial start and another survey at the trial end. Trial participants will be able
to access them through the messaging service of the platforms.
The training material questionnaire
The training material will be assessed from the results of a survey that will be given to patients after the training
period  to  determine  whether  the  patients  and their  informal  caregivers  found the  training  materials  useful  and
informative.  Data will  be  gathered on user  experience and whether  users  feel  more  knowledgeable  about  their
conditions and if they feel enabled to use C3-Cloud to take care of their conditions after the training. It will also
consider whether the materials are a contributing factor to improve care coordination. 
The questionnaire for user interaction satisfaction (QUIS) 
Similar to the early usability testing with a limited number of test users, the QUIS7 questionnaire[CITATION Nor19 \l 1031
] will be used for both MDT members and patients when the technology trial is in full scope and will be conducted
partly after the initial user-training at the beginning of the trial and partly at the end of the trial. The results from both
questionnaires compared and used, in an iterative fashion,  for shaping the design and redesign of  the C3-Cloud
platform and for providing potential recommendations for areas of improvement.
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The Unified Theory of Acceptance and Use of Technology questionnaire (UTAUT)
A C3-Cloud-adapted version of the UTAUT questionnaire [ CITATION Ven03 \l 1031 ] will be used, covering some of the
original UTAUT modules. The UTAUT is developed to predict individual adoption and use of new ITs. It posits that
individuals’ behavioural intention to use an IT is determined by two beliefs: perceived usefulness, defined as the
extent to which a person believes that using an IT will enhance his or her job performance and perceived ease of use,
defined as the degree to which a person believes that using an IT will be free of effort. A limited UTAUT version will be
conducted at the beginning of the pilot trial, just after participants) have had training sessions on how to use the C3-
Cloud components. This version includes the following UTAUT modules: performance expectancy, effort expectancy,
social influence, technology anxiety, adoption timeline and behavioural intention. The questionnaire will be repeated
in a more comprehensive version shortly before the end of the trial.  This second version includes the additional
modules: cultural trends and language factors. The results from the initial UTAUT will be compared to the closure
UTAUT questionnaire in order to evaluate the differences in acceptance and use of C3-Cloud technology over the trial
duration. 
Phase 4 
Phase 4 will carry out the modelling for large scale impact of C3-cloud implementation after the technology trial. The
health and economic benefits of the intervention at population level will be evaluated to generate insights on savings
that C3-Cloud could generate systemically in the long term. The digitalisation of clinical patient histories and the
coding of all contacts between patients and their MDTs into the EHR, allows to better understand the health demand
of a population and to quantify the health and social burden of the disease. Because of that, healthcare resource
usage data of all patients will be used and compared using modelling techniques with anonymous comparator patient
data. The modelling tool used for this analysis has been developed by merging discrete event simulation modelling
methods with a cost-benefit assessment tool [ CITATION Ham14 \l 1031 ]. The merger tool (Table 5) will help predict the
return on investment and time to break even for integrated care implementation at large-scale. It  will be used to
inform decision making in the management of integrated care in general and on the expected impact of scaling up
the  use  of  C3-Cloud. The  aim  is  to  develop  a  combined  tool  taking  advantage  of  two  existing  approaches
(ASSIST[ CITATION Ham14 \l 1031 ] and predictive modelling [ CITATION Lar18 \l 1031 ],[ CITATION Sot17 \l 1031 ]) that have
been previously applied in other European projects like CareWell  [CITATION emp19 \l  1031 ] and smartcare[CITATION
emp191 \l 1031 ] . Merging them aims to improve reliability and validity of the tool by incorporating the comprehensive
perspective applied by ASSIST and the flexible engine developed in predictive modelling to represent mathematically
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the natural history of the disease. The conceptual model includes not only the health system but also the complete
set of stakeholders. Model parameterization is a challenge as data required for all stakeholders cannot probably be
obtained from evidence-based sources. The data will focus on healthcare resource utilization, frequency of use of C3-
Cloud  components  and  service  satisfaction.  The  data  needed  for  this  type  of  modelling  will  be  taken  from
administering additional questionnaires to participants: the eCare client impact survey (eCCIS) for patients, the eCare
user impact survey (eCUIS) for MDT members and a few additional questionnaire items for patients, MDT members
and informal care givers. 
In addition, C3-Cloud logfiles and EHR exports will be taken from electronic health records of the intervention and also
from comparator patients in order to evaluate the differences in healthcare resource utilization during the trial. This
includes  for  example:  changes  to  drug  use;  re-admissions;  number  of  adverse  drug  events;  number  of  virtual
sessions;  or  resource  redistribution.  The  comparator  group  will  be  taken  from another  practice  and  statistically
adjusted for the differences based on historic data.
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Assist cost-benefit analysis tool Predictive modelling
ASSIST  is  an  assessment  and  evaluation  tool
originally  developed  for  use  in  the  context  of
telemedicine  and  telehealth  services,  specifically
to  assess  the  economic  viability  of  telemedicine
pilot projects  [  CITATION Ham14 \l  1031  ].  During the
validation phase, ASSIST was successfully applied
by five telemedicine projects. A core aim of ASSIST
is to facilitate the transposition of a pilot project
into  routine  service  operation  and  to  support
service  providers  in  achieving  a  sustainable
economic model where service benefits are higher
than  service  costs.  It  also  facilitates  the
transposition of a pilot project into routine service
operation  and  supports  service  providers  in
achieving  a  sustainable  economic  model.  The
assessment  process  of  the  tool  includes  three
steps:   1)  Service  assessment  model  setup:  the
service  change  is  analysed  to  identify  the  key
components  like  applicable  governance  and  the
reimbursement  model,  stakeholders  and  the
financial  impacts  (costs  and  benefits   on  the
stakeholders); 2) Data collection and monetization
and  3)  Calculation  of  performance  measure:  the
main  outcome measure  is  based  on  the  ratio  of
total costs to total benefits, i.e. including financial
costs and benefits, resource costs and benefits and
intangible costs and benefits.
Modelling  serves  to  calculate  the  Budget  Impact
Analysis  (BIA)  by  reproducing  the  natural  history  of
multi-morbid patients in both the standard scenario and
the new scenario related to the new intervention which
results in implementation, effectiveness (i.e. how does
new intervention affect the number of contacts to health
professionals) and costs. A BIA projects the burden of
the  target  population  within  the  conventional  or
baseline scenario and analyses how this burden would
change if the intervention achieved the organizationally
defined goal. 
Table 5: Predictive modelling
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The eCare Client Impact Survey (eCCIS) and the eCare User Impact Survey (eCUIS)
The eCCIS and eCUIS will be used to evaluate the utility that the C3-Cloud application brings to the patients and MDT
members. It measures how patients and informal carers perceive the utility of C3-Cloud. To this can be added scales
addressing time use, willingness-to-pay and perception of care integration. In addition, the overall satisfaction with
the C3-Cloud system as a service,  whether the service is  worth the effort involved in using it  and whether the
respondent would want to continue using the service or to use it again is evaluated. 
Additional questionnaire items
A few questionnaire items have been added to the surveys to evaluate the impact of C3-Cloud implementation on
patients, their informal caregivers, MDT members and the wider service system. This will be administered early in the
trial and again at the end. The evaluation uses open and closed questionnaires, targeting patients and MDT members.
It  will  evaluate the impact of  the different software components and focuses on the following evaluation topics:
usefulness; ease of use/usability; safety; process quality and changes and the respondents’ perspective on clinical
optimization.
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Medical devices
In addition, medical sensor device usage and connected device usage will be evaluated with a sub-set of patients at
RJH pilot site only. Patients will be individually selected from the group of intervention patients at the discretion of
local clinicians. The testing serves to evaluate the technical possibility of including sensor and connected devices as
part of the patient care planning.
Results 
The  evaluation  phases  1  and  2  were  completed  in  winter  2018. It  included  feedback  regarding  the  system
components, the application and the usability of the platform. 
Results of phase 1:
System  components  testing:  Each  component  owner  checked  and  verified  that  the  implemented  component
functionalities  meet  the  specified  requirements.  The  testing  was  documented  in  accordance  to  the  IEEE  829
[ CITATION IEE08 \l 1031 ] including a component test plan, the test design and execution procedure as well as test
results  presenting  the  test  data,  incident  reports  and  a  conclusion.  The  test  team comprised  experts  from the
component developers as well as owners of the other components.
Usability  testing:  C3DP  mock-ups  were  presented  first  as  a  series  of  screenshots  to  four  health  ICT  experts  in
September 2016. Between October 2016 and December 2016, clinicians and patients from the pilot  sites in the
Basque Country (11 MDTs and 9 patients) and Jämtland Härjedalen (4 MDTs and 12 patients) performed the tests. The
pilot  site in South Warwickshire performed the test in autumn 2017 (7 MDTs and 5 patients).  This  later version
consisted of a real online demonstrator, during which testers gave direct feedback on the screen. 
Results of phase 2:
For phase 2 test sessions a total of 20 MDT members and 27 patients were recruited across the three pilot sites: 6
MDTs and 2 patients in the Basque Country; 2 MDTs and 12 patients in Region Jämtland and 12 MDTs and 13 patients
in South Warwickshire. Convenience sampling was applied among people with sufficient English language proficiency.
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Convenience sampling was used as it has shown that specifically phase 2 was difficult to perform due to language
barriers. It implies a massive increase in efforts if the system demonstrator as well as training was translated to all
three languages already at an early stage. Thus it was decided to recruit test users with sufficient English language
proficiency in the three pilot sites. The early usability test results obtained with the QUIS7 survey were aggregated
and a descriptive analysis was provided to the software developers for subsequent improvement. The Delphi method
was used to formulate overall 57 questions; 33 for MDTs and 24 for patients and informal caregivers. The results of
evaluation phases 1 and 2 were published at MedInfo 2019 [CITATION Tra19 \l 1031 ].
The pilot  testing (phase 3) was launched in July 2019. Data collection is  underway and results are forthcoming.
Difficulties were experiences in recruiting the envisaged trial participants, specifically with the intervention patients
(Table 6).
Pilot Region Intervention patients MDT members
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5
45 230 tbd 12
2
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Planned 175+44
+35 =
254
2
1
9
17
5
0 50/
50
30
Actual 692 2
2
3
21
0
0 tbd 30 3  patients  deceased  during
study  trial  delay.  Another  10
patients  withdrew  their
consent before trial start.
MDTs  include  20  doctors,  10
nurses
Total 610 27
6
230 16
8
-
Table 6: Number of trial participants (summary)
The technology trial protocol was submitted in several revisions to the three regional ethics committees in reflection
of updates regarding project information that would be communicated to trial participants; the way of involvement of
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control group patient data the recruitment procedure of for patients; trial participants training or adaptations to some
questionnaires.
Evaluation results of the pilot technology trial are anticipated to become available by mid-2020.
Strengths of  the approach taken are that it  allows for  an early  feedback to the software developers  for  further
improvement of the software before starting the technology trial with an increased number of patients and MDT
members  in  real  settings.  The  combination  of  structured  and  unstructured  feedback  from  the  test
sessions complemented each other. However, the validity of test results may be reduced based on the dependency
on test participant’s fluency in the English language and the unequal distribution of test users across the pilot sites.
Discussion
Many older people suffer with more than one illness. Managing these illnesses can be very challenging for patients
and healthcare service providers. In response to these challenges, the C3-Cloud project evaluation activities in phases
1-4, including a technology trial  will  determine whether the C3-Cloud computer system can improve the care of
patients aged 55 & over who have more than one long term condition. The C3-Cloud system is designed so that
patients can work more closely with their healthcare professionals to create, develop and manage their personal care
plans.  The  platforms  enable  care  plans  to  be  personalised  for  multi-morbid  conditions  through  systematic  and
semiautomatic  reconciliation  of  digitally  represented  clinical  guidelines.  This  paper  has  presented  the  research
protocol  of  the  C3-Cloud  technology  trial  as  well  as  the  development  of  the  C3-Cloud  platforms.  C3-Cloud  has
developed  a  modified  impact  modelling  tool  in  phase  4  (a  merged  tool  of  the  ASSIST  tool  and  the  predictive
modelling), for informing integrated care management on a large scale deployment potential of systems such as C3-
Cloud. Results will be published in forthcoming project publications. The number of patients and MDT members varies
across the three pilot sites based on convenience sampling as participation depends fully on the commitment of the
pilot site organizations. Their commitment was and is crucial to conduct the technology trial throughout the different
phases.
The research design leans on the MRC guidance for complex interventions[ CITATION Cra08 \l 1031 ]. The usefulness of
complex interventions is determined also by the way they are implemented [CITATION Sot19 \l 1031 ]. C3-Cloud is in an
early development and implementation phase and solutions need thorough testing along various dimensions to better
understand the benefits of ICT in health care and to respond to the challenge of implementing complex interventions.
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Much of the results will be available as open published results and to some extent as open source software for other
parties to make use of. It is likely but dependent on the evaluation of the project that the present technical solutions
will be offered for routine expanded use in the three pilot regions and of course also in a wider scale throughout these
countries. The strong inclusion and commitment by the public health care organisations in the three regions implies
that there is a strong probability of the results to be taken further after the study period transformed into routine
improved health care services for this important group of patients. Trial evaluation results will become available and
be  published  at  project  end  (summer  2020)  and  report  further  on  difficulties  experiences  when  following  the
presented  research  protocol.  Future  research  will  include  the  possible  reorganization  of  multi-professional  care
services for elderly patients using collaboration tool such as C3-Clouds. Also the establishment of more decision
support based on clinical guidelines for other conditions than the four diseases tested in the project.
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BC Basque Country
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https://preprints.jmir.org/preprint/21994 [unpublished, non-peer-reviewed preprint]
JMIR Preprints von Tottleben et al
References
 CITATION Lup08 \l 1031 : , [1], 
 CITATION Ret12 \l 1031  : , [2], 
 CITATION Aus07 \l 1031  : , [3], 
 CITATION Gut12 \l 1031  : , [4], 
 CITATION NHS13 \l 1031 : , [5], 
 CITATION Haq09 \l 1031 : , [6], 
 CITATION Pav12 \l 1031 : , [7], 
 CITATION Gel11 \l 1031  : , [8], 
 CITATION Eva16 \l 1031 : ,  [9], 
 CITATION Cra08 \l 1031 : , [10], 
 CITATION Bar19 \l 1031 : , [11], 
 CITATION IEE08 \l 1031 : , [12], 
CITATION Tra18 \l 1031 : , [13], 
 CITATION Dal631 \l 1031 : , [14], 
 CITATION Bar10 \l 1031 : , [15], 
 CITATION Ben02 \l 1031 : ,  [16], 
 CITATION Dal631 \l 1031  : , [14], 
 CITATION Nor19 \l 1031 : ,  [17], 
 CITATION Ben02 \l 1031 : , [16], 
 CITATION Nie951 \l 1031 : ,  [18], 
CITATION Nor19 \l 1031 : ,  [17], 
 CITATION Ven03 \l 1031 : , [19], 
 CITATION Ham14 \l 1031 : , [20], 
 CITATION Ham14 \l 1031 : ,  [20], 
 CITATION Lar18 \l 1031 : , [21], 
 CITATION Sot17 \l 1031 : ,  [22], 
CITATION emp19 \l 1031 : , [23], 
CITATION emp191 \l 1031 : ,  [24], 
CITATION Tra19 \l 1031 : , [25], 
 CITATION Cra08 \l 1031 : ,  [10], 
https://preprints.jmir.org/preprint/21994 [unpublished, non-peer-reviewed preprint]
JMIR Preprints von Tottleben et al
CITATION Sot19 \l 1031 : , [26], 
[1] F. Luppi, B. Beghe and L. M. Fabbri, Treatment of chronic obstructive pulmonary disease and its comorbidities, procAm Thorac, Cited in
the EIP-AHA Operational Plan, 2008. 
[2] European Commission, “Communication from the Commission to the European Parliament and the Council: Taking forward the Strategic
Implementation  Plan  of  the  European  Innovation  Partnership  on  Active  and  Healthy  Ageing,”  2012.  [Online].  Available:  https://eur-
lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A52012DC0083.
[3] Australian Institute of Health and Welfare, “Comorbidity of cardiovascular disease, diabetes and chronic kidney disease in Australia,” 2007.
[Online]. Available: https://www.aihw.gov.au/getmedia/63851abe-7339-4730-bd82-02dc647690be/cocddackdia.pdf.aspx?inline=true.
[4] B. Guthrie, K. A. P. Payne, M. E. T. McMurdo and S. W. Mercer, “Adapting clinical guidelines to take account of multimorbidity,” British
Medical Journal, p. 345. e6341., 04 October 2012. 
[5] NHS Improvement-Lung, “Managing multi-morbidity in practice, what lessons can be learnt from the care of people with COPD and co-
morbidities?,” 2013. [Online]. Available: https://www.educationforhealth.org/wp-content/uploads/2015/03/COPD_MultiMorbidities.pdf..
[6] R. Haque, “ARMOR: A Tool to Evaluate Polypharmacy in Elderly Persons,” Annals of Long-Term Care, 2009.
[7] A. Pavlickova,  “EPPOSI AIP-CCM White  Paper:  Building a  Workable Model  for the Holistic  Management  of  Chronic Conditions  in
Europe,” Science & Industry, Brussels, 2012.
[8] W. F. Gellad, J. L. Grenard and Z. A. Marcum, “A systematic review of barriers to medication adherence in elderly: looking beyond cost and
regimen complexity,” Am J Geriatr Pharmacother, 9(1), pp. 11-23, 2011. 
[9] R. S. Evans, “Electronic Health Records: Then, Now, and in the Future Yearb Med Inform. Suppl 1(Suppl 1):,” in  Yearbook of Medical
Informatics, vol. 1, Thieme, 2016, p. 48–61.
[10] P. Craig, P. Dieppe, S. Macintyre, S. Michie, I. Nazareth and M. Petticrew, “Developing and evaluating complex interventions: the new
Medical Research Council guidance,” BMJ, p. 337:a1655, September 2008. 
[11] Sector  Sanitario  de  Barbastro,  “SUSTAINS  Project,”  [Online].  Available:
http://sectorbarbastro.salud.aragon.es/en/innovation/finished/sustains. [Accessed 18 10 2019].
[12] IEEE, “IEEE Standard for Software and System Test Documentation,” IEEE Std 829-2008, pp. 1-150, 18 July 2008. 
[13] C3-Cloud project (EU H2020 grant agreement #689181), “Deliverable D9.3: Test and Evaluation Report for C3-Cloud Components,” 2018.
[14] N. Dalkey and O. Helmer, “An experimental application of the Delphi method to the use of experts,” Management science, 9(3), pp. 458-
467, 1963. 
[15] C.  Barnum and  L.  Palmer,  “More  than  a  feeling:  understanding  the  desirability  factor  in  user  experience,”  in  More  than  a  feeling:
understanding the desirability factor in user experience, 2010. 
[16] J. Benedek and T. Miner, “Measuring Desirability: New methods for evaluating desirability in a usability lab setting,” 2002.
[17] K. Norman, B. Shneiderman, B. Harper and L. Slaughter, “QUIS: Questionnaire for User Interaction Satisfaction 7.0,” [Online]. Available:
https://preprints.jmir.org/preprint/21994 [unpublished, non-peer-reviewed preprint]
JMIR Preprints von Tottleben et al
https://isr.umd.edu/news/news_story.php?id=4099. [Accessed 11 September 2019].
[18] J. Nielsen, “How to Conduct a Heuristic Evaluation,” 1 November 1994. [Online]. Available: https://www.nngroup.com/articles/how-to-
conduct-a-heuristic-evaluation/. [Accessed 11 September 2019].
[19] V. Venkatesh, M. G. Morris and G. B. Davis, “User acceptance of information technology: Toward a unified view,” MIS Quarterly, pp. 425-
478, 2003. 
[20] R.  Hammerschmidt  and  I.  Meyer,  “Achieving  Effective  Integrated  E-Care  Beyond the  Silos,”  in  Chapter  7:  Socio-Economic  Impact
Assessment and Business Models for Integrated eCare, Pennsylvania, igi-global, 2014, pp. 135-163.
[21] I. Larrañaga, P. Stafylas, A. Fullaondo, G. Apuzzo and J. Mar, “Economic evaluation of an integrated health and social care program for
heart failure through 2 different modeling techniques,” Health Services Research and Managerial Epidemiology, vol. 5, pp. 1-6, 2018. 
[22] M. Soto-Gordoa, A. Arrospide, M. Merino Hernandez, J. Mora Amengual, A. Fullaondo Zabala, L. I., E. de Manuel Keenoy and I. Mar,
“Incorporating budget impact analysis in the implementation of complex interventions: A case of an integrated intervention for multimorbid
patients within the CareWell study,” Value in Health, vol. 20, pp. 1-7, 2017. 
[23] empirica GmbH, “CareWell project,” [Online]. Available: http://carewell-project.eu/. [Accessed 06 September 2019].
[24] empirica GmbH, “smartcare project,” [Online]. Available: http://pilotsmartcare.eu/. [Accessed 06 September 2019].
[25] L. Traore, A. Assele-Kama, S. N. L. C. Keung, L. Karni, G. O. Klein, M. Lilja, I. Scandurra, D. Verdoy, M. Yuksel, T. N. Arvanitis, R. Tsopra
and  M.-C.  Jaulent,  “User-centred  design  of  the  C3-Cloud  platform for  elderly  with  multiple  diseases  –  functional  requirements  and
application testing,” Studies in Health Technology and Informatics, vol. 264, pp. 843-847, 2019. 
[26] M. Soto-Gordoa, E. de Manuel Keenoy, A. Fullaondo, M. Merino, A. Arrospide, J. Igartua and J. Mar, “Impact of stratification on the
effectiveness of a comprehensive patient-centered strategy for multimorbid patients,” Health Services Research, vol. 54, no. 2, pp. 466-473,
2019. 
[27] A. Eckhardt, S. Laumer and T. Weitzel, “Who influences whom? Analyzing workplace referents’ social influence on IT adoption and non-
adoption,” Journal of Information Technology, 2009. 
[28] V. J.P., E. von Elm, D. G. Altman, P. C. Gøtzsche, C. D. Mulrow, S. J. Pocock, C. Poole, J. J. Schlesselman and M. Egger, “Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) Explanation and Elaboration. ).,” Epidemiology, pp. 805-35, 18 November
2007. 
https://preprints.jmir.org/preprint/21994 [unpublished, non-peer-reviewed preprint]
JMIR Preprints von Tottleben et al
Inclusion diagnosis codes for patient screening
The exact diagnosis codes used in the pilot sites to screen for eligible patients are listed in the following table.
Condition   READ  Codes:  South
Warwickshire 
ICD-10  /  ICD-9  Basque
Country  and  Jämtland
Härjedalen 
Type II Diabetes  Type  2  Diabetes: C10F**
(including all codes below
in the code tree) 
Diabetes = E11 
Diabetes with CF=
E11.2 or I13.0 
Diabetes with complications =
E11.8P 
ATC = N06A 
Renal  Failure
with eGFR/  GFR 30 –
59  (measured  or
estimated glomerular fi
ltration rate) 
K05* (Chronic  renal  failure)  and
all codes below in the tree. 
 
1Z1* (chronic  renal
impairment) (including all  codes
below in the code tree) 
RF  =
N18.9 or I12.0 or I13.1 or N19
.9 or N19.-P or N18.2  to
N18.5 
Hypertension  +RF+  CF  =
I13.2 
Heart  Failure  in
compliance  with
NYHA I-II (New York
Heart  Association
classification  of  heart
failure) 
C58* (including all  codes  below
in the code tree) 
 
420300004  (NYHA Class  I)  and
421704003  (NYHA  Class
II) classification will be an
individual check by a GP 
CF= I50 or I11.0 
Diabetes with CF=
E11.2 or I13.0 
Hypertension  +RF+  CF  =
I13.2 
Mild  or  moderate
depression in adults 
Anxiety with depression – include
all. (Read Code: E2003) 
Depression  NOS  –  include  all.
Depression = F32.9 
 or F32.1  
or F33.1  
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(Read Code: Eu32z-1) 
Depressive episode, unspecified –
include all. (Read Code: Eu32z) 
Endogenous depression – include
all. (Read Code: E112-4) 
Reactive depression NOS include
all. (Read Code: Eu32z-4) 
Chronic depression – include all.
(Read Code: E2B1) 
Recurrent  depression  –  include
all. (Read Code: E1137) 
Endogenous depression  –
recurrent  –  include all.  (Read
Code: E113-1) 
Low  Mood  –  include  all.  (Read
Code: 1BT-1) 
or F32.0  
or F32-  
or F33- 
 Table : Diagnosis codes used for patient screening
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Multimedia-appendix 
Description   Website
C3-Cloud  project
website
http://c3-cloud.eu/
Project video
https://youtu.be/2lvff9kjUxo
Project short video
https://youtu.be/Y3K_lUQkupg
Surveys  used  in  the
evaluation phases https://c3-cloud.eu/c3-cloud_surveys_09_oct_2019/
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